An analyst sees good growth prospects for Xeris Biopharma Holdings Inc (XERS)

With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.36 million shares. The 52-week range on XERS shows that it touched its highest point at $3.26 and its lowest point at $1.46 during that stretch. It currently has a 1-year price target of $4.75. Beta for the stock currently stands at 1.63.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XERS was down-trending over the past week, with a drop of -0.95%, but this was down by -34.28% over a month. Three-month performance dropped to -11.06% while six-month performance rose 12.37%. The stock gained 43.15% in the past year, while it has lost -11.06% so far this year. A look at the trailing 12-month EPS for XERS yields -0.45 with Next year EPS estimates of -0.15. For the next quarter, that number is -0.11. This implies an EPS growth rate of 23.17% for this year and 57.78% for next year.

Float and Shares Shorts:

At present, 138.13 million XERS shares are outstanding with a float of 125.33 million shares on hand for trading. On Mar 15, 2024, short shares totaled 9.24 million, which was 6.58% higher than short shares on Feb 15, 2024. In addition to VERS as the firm’s VERS, CERS serves as its Cerus Corporation.

Institutional Ownership:

Through their ownership of 44.82% of XERS’s outstanding shares, institutional investors have minority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XERS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, XERS has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and XERS currently yields $0.00. In the past year, XERS’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, XERS has a current buyback yield of $0.34. This was $0.34 for the TTM, and it was $– for the past five years.